Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally

Fineline Cube Dec 10, 2025
Company Deals

Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal

Fineline Cube Dec 10, 2025
Company Deals

Shandong Boan Licenses US Rights for Denosumab Biosimilars to Nanjing Kingfriend in $75 Million Deal

Fineline Cube Dec 10, 2025
Company Deals

Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development

Fineline Cube Dec 10, 2025
Company Deals

Lee’s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership

Fineline Cube Dec 10, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing

Fineline Cube Dec 11, 2025
Company Drug

Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer

Fineline Cube Dec 10, 2025
Company Drug

Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval

Fineline Cube Dec 2, 2025

Abbisko Cayman Limited (HKG: 2256) announced that its Investigational New Drug (IND) application for ABSK141,...

Company Drug

AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China

Fineline Cube Dec 2, 2025

AbbVie (NYSE: ABBV) announced that Rinvoq (upadacitinib) has been included in the priority review list...

Company Drug

Lynk Pharma LNK01006 FDA Approval Targets TYK2 for CNS Diseases

Fineline Cube Dec 2, 2025

Lynk Pharmaceuticals Co., Ltd. announced that its self‑developed TYK2 allosteric inhibitor LNK01006 has received FDA...

Others

FDA Prasad Outlines New Vaccine Approval Process After Covid-19 Safety Analysis

Fineline Cube Dec 2, 2025

Dr. Vinay Prasad, FDA’s chief medical and scientific officer, announced plans to overhaul the vaccine...

Hospital Policy / Regulatory

China Health: Life Expectancy Hits 79 Years as Hospitals Expand and Expenditure Controlled

Fineline Cube Dec 2, 2025

The National Health Commission released the Statistical Bulletin on China’s Health Undertakings 2024, showing China’s...

Company Drug

CANbridge’s maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus

Fineline Cube Dec 2, 2025

CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that maralixibat has been approved by the Department of...

Company Deals

WuXi Biologics CRDMO Qatar MOU Establishes First Middle East Center

Fineline Cube Dec 2, 2025

WuXi Biologics (HKG: 2269) announced it has signed a strategic Memorandum of Understanding (MOU) with...

Company Drug

Johnson & Johnson’s Nipocalimab Secures EU Approval for Myasthenia Gravis

Fineline Cube Dec 2, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission has granted Marketing Authorisation...

Company Deals

Regeneron Tessera Partner on TSRA-196 Gene-Writing Therapy for AATD with $275M Deal

Fineline Cube Dec 2, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Tessera Therapeutics announced a global collaboration to develop and...

Company Deals

ChemPartner and Fosun Pharma Forge CRO-CDMO Alliance to Accelerate Drug Development

Fineline Cube Dec 2, 2025

Shanghai ChemPartner Co., Ltd. (SHE: 300149) and Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG:...

Company Medical Device

Microport’s PulseMagic PFA-Catheter Secures NMPA Approval as First Pressure-Monitoring Device in China

Fineline Cube Dec 1, 2025

Shanghai Microport EP Medtech Co., Ltd (SHA: 688351) announced that its PulseMagic TrueForce Disposable Pressure-Monitoring...

Company Drug

Humanwell’s HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction

Fineline Cube Dec 1, 2025

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Class 1 biological product HWS117 injection...

Company Deals

Sanyou Bio and FatiAbGen Forge AI-STAL Alliance for Korea and Global Markets

Fineline Cube Dec 1, 2025

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and South Korea’s FatiAbGen Co., Ltd. announced a comprehensive strategic...

Company Drug

Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND

Fineline Cube Dec 1, 2025

Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37 oral tablets, its first GLP‑1R/GIPR/GCGR...

Company Drug

Mabwell’s 9MW1911 Cuts COPD Exacerbations by 30% in Phase 2a, FDA Accepts US Trial Application

Fineline Cube Dec 1, 2025

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that its ST2‑blocking monoclonal antibody 9MW1911 has...

Company Deals Drug

Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR‑T Combination for Advanced Solid Tumors

Fineline Cube Dec 1, 2025

Imugene Ltd (ASX: IMU) and JW Therapeutics (Shanghai) Co., LTD (HKG: 2126) announced a co‑development...

Company Deals

Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech

Fineline Cube Dec 1, 2025

Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced the establishment of the Wuhan Ruicheng New...

Company Drug

iRegene’s NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy

Fineline Cube Dec 1, 2025

iRegene Therapeutics announced that the U.S. FDA granted Special Exemption status to NouvNeu004 injection, approving...

Company Deals

Proviva’s PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost

Fineline Cube Dec 1, 2025

Proviva Therapeutics announced the completion of a Series A+ financing round, raising over USD 30 million led...

Company Drug

Pfizer-Astellas’ PADCEV Wins FDA Approval for Perioperative Bladder Cancer

Fineline Cube Nov 29, 2025

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food...

Posts pagination

1 … 3 4 5 … 596

Recent updates

  • Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing
  • D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally
  • Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal
  • Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer
  • Innovent Doses First Patient in Phase 1 Trial of IBI3011, China’s First Anti‑IL‑1RAP Antibody for Gout Flares
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing

Company Deals

D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally

Company Deals

Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal

Company Drug

Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.